Takeda was declared the best global employer for the sixth year in a row

OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Takeda (TSE:4502/NYSE:TAK) announced today that, for the sixth year in a row, it is one of only 15 companies to receive global Top Employer® certification for 2023. Along with global certification, Takeda is also recognized as a Top Employer in 22 countries, reinforcing its commitment to creating a diverse, fair and inclusive working environment and exceptional employee experience.

The Top Employers Institute program certifies organizations based on the participation and results of their best HR practices survey. This research covers six HR domains comprising 20 topics including people strategy, work environment, talent acquisition, learning, diversity and inclusion, wellbeing and more.

We are steadfast in our commitment to creating a culture that fosters collaboration, well-being and resilience, and this recognition from the Top Employers Institute as a Best Global Employer further underscores that focus,” said Lauren Duprey, Chief Human Resources Officer, Takeda. “The work we do changes lives, helping patients around the world with little or no treatment options, and our people are the cornerstone of everything we achieve. Our people operate with a purpose and we are proud to provide them with a work environment that enables them to succeed.”

Extraordinary times bring out the best in people and organizations, and we witnessed this in our Top Employers certification program this year: the exceptional performance of the certified Top Employers 2023. Among this community of extraordinary organizations, Takeda has proven its commitment to its employees on a global scale,” said David Plink , Chief Executive Officer, Top Employers Institute. “This consistency in the practices of people around the world characterizes the exclusive group of companies that have achieved global certification through the Top Employers program. We are proud to announce and celebrate these companies and their achievements in 2023.”

Takeda has excelled globally in the areas of ethics and integrity, purpose and values, business strategy, employer branding, and organization and change. Each of the 22 Takeda countries and regions participating in the Top Employer survey received certification, including Canada for the first time. The complete list of countries in which Takeda has been named the best employer can be found below:

  • Asia Pacific: Australia, China, India, Japan, South Korea
  • Europe: Austria, France, Germany, Ireland, Italy, Poland, Portugal, Spain, Switzerland, United Kingdom.
  • Latin America: Argentina, Brazil, Colombia, Mexico
  • Middle East: Israel
  • North America: Canada and the United States

To learn more about the Top Employers Institute and the Top Employers certification, visit: https://www.top-employers.com.

About Takeda

Takeda is a values-based, R&D-driven global biopharmaceutical leader headquartered in Japan, dedicated to discovering and delivering life-changing treatments, driven by our commitment to patients, our people and the planet. Takeda focuses its research and development efforts on four therapeutic areas: oncology, rare genetics and hematology, neuroscience and gastroenterology (GI), with expertise in immune and inflammatory diseases. We also make targeted investments in research and development of therapies and vaccines derived from plasma. We are focused on developing highly innovative medicines that make a difference in people’s lives by advancing the frontiers of new treatment options and leveraging our enhanced collaborative research and development engine and capabilities to create a robust multi-modality pipeline. Our employees are committed to improving the quality of life for patients and collaborating with our healthcare partners in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session, and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) in connection with with this announcement. This press release (including any oral briefing and any Q&A related thereto) is not intended to constitute, constitute or form part of any offer, solicitation or solicitation of any offer to purchase, otherwise acquire, subscribe be, exchange, sell or otherwise dispose of any securities or seek any vote or approval in any jurisdiction. No shares or other securities are being offered to the public through this announcement. No securities may be offered in the United States except pursuant to registration under the US Securities Act of 1933, as amended, or an exemption therefrom. This press release is provided (together with any further information that may be provided to the recipient) on the condition that the recipient use it for informational purposes only (and not to evaluate any investment, acquisition, disposition or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

Companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience when referring to Takeda and its subsidiaries generally. Likewise, the words “we”, “us” and “our” are also used to refer to affiliates generally or those working for them. These terms are also used when the identification of a particular company or companies serves no useful purpose.

Leave a Reply

Your email address will not be published. Required fields are marked *